Nepicastat oral

Drug Profile

Nepicastat oral

Alternative Names: DBH inhibitor programme; DβH inhibitor programme; Nepicastat hydrochloride; SYN-117

Latest Information Update: 02 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Biotie Therapies Corp.
  • Class Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Imidazoles; Neuropsychotherapeutics; Small molecules; Thiones
  • Mechanism of Action Dopamine beta hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cocaine abuse; Parkinson's disease; Post-traumatic stress disorders

Most Recent Events

  • 27 May 2014 The National Institute on Drug Abuse & Biotie complete enrolment in a phase II trial for Cocaine abuse in USA (NCT01704196)
  • 22 May 2014 Phase-II development is ongoing in USA
  • 13 May 2013 Biotie Therapies initiates enrolment in a phase II trial for Cocaine abuse in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top